
BrickBio develops a bioconjugation platform for optimized, site-specific protein modification research.
Founded with the mission to revolutionize protein engineering, BrickBio focuses on developing a bioconjugation platform for site-specific protein modification. The company's innovative technology allows for the precise and selective modification of proteins, enhancing research capabilities in both prokaryotic and eukaryotic systems. Their platform is designed to optimize conjugates, providing researchers with advanced tools for protein engineering and therapeutic development.
BrickBio has garnered attention from notable investors and industry experts, contributing to its rapid growth and recognition within the biotech sector. The company's achievements include successful collaborations with leading research institutions and biotech firms, demonstrating the practical applications and benefits of their platform. BrickBio's impact is evident in its contribution to advancing protein engineering, offering significant potential for breakthroughs in medical research and drug development.

Catena Biosciences

BridGene Biosciences

Monod Bio
monod.bio

Adaptyv Biosystems
adaptyvbio.com

Evozym Biologics

Protillion Biosciences
protillion.com

Rbio
rbio.online

BioHybrid Solutions

Manifold Bio
manifold.bio

AI Proteins
aiproteinstx.com

BridgeBio Pharma
bridgebio.com

Ginkgo Bioworks
ginkgobioworks.com

Protein Dynamic Solutions
pdsbio.com

Vulcan Biologics

Glyphic Biotechnologies
glyphic.bio
Companies similar to BrickBio include Catena Biosciences, BridGene Biosciences, Monod Bio and Adaptyv Biosystems.
BrickBio was founded in 2019.
BrickBio's headquarters is located in Boston, MA, US.
BrickBio's most recent funding round was for $5M (USD) in November 2019.
As of Nov 22, 2019, BrickBio has raised a total of $5M (USD).
BrickBio has 9 employees as of Feb 5, 2024.